SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Sonoma Pharmaceuticals, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.12+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $4.31M
- P/E (TTM)
- –
- Dividend yield
- –
Sonoma Pharmaceuticals, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | TTM Q2 21 | TTM Q1 21 | TTM Q4 20 | TTM Q3 20 | TTM Q2 20 | TTM Q1 20 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $11.27M | $11.93M | $11.08M | $11.04M | $11.45M | $12.18M | $20.22M | $19.16M | $17.78M | $17.58M | $18.25M | $18.17M | 96.4% | -1.6% |
| Service [Member] | $416.00K | $1.35M | $1.33M | $1.32M | $1.32M | $449.00K | – | – | $151.00K | $1.16M | $1.09M | $1.14M | 3.6% | -68.5% |
| Animal Skin Care [Member] | – | – | – | – | – | – | – | – | – | $2.51M | $2.20M | $1.85M | – | – |
| Human Care [Member] | – | – | – | – | – | – | – | – | – | $15.19M | $16.16M | $16.43M | – | – |
By region
From the segment and revenue-disaggregation notes of Sonoma Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.